Opsens Inc. (TSE:OPS – Get Rating) – Analysts at Raymond James reduced their Q1 2023 earnings estimates for Opsens in a research note issued to investors on Wednesday, September 7th. Raymond James analyst R. Sarugaser now expects that the company will earn ($0.03) per share for the quarter, down from their prior estimate of ($0.02). Raymond James currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Opsens’ current full-year earnings is ($0.06) per share. Raymond James also issued estimates for Opsens’ Q4 2023 earnings at ($0.03) EPS, FY2023 earnings at ($0.12) EPS, FY2024 earnings at ($0.08) EPS and FY2026 earnings at $0.14 EPS.
Opsens Trading Down 1.4 %
TSE OPS opened at C$2.74 on Monday. The stock has a market capitalization of C$298.03 million and a P/E ratio of -46.44. Opsens has a 52-week low of C$1.55 and a 52-week high of C$3.74. The firm has a 50-day moving average price of C$2.55 and a 200 day moving average price of C$2.20. The company has a quick ratio of 4.88, a current ratio of 5.87 and a debt-to-equity ratio of 18.46.
Opsens Inc develops, manufactures, installs, and sells fiber optic sensors for interventional cardiology, fractional flow reserve (FFR), oil and gas, and industrial applications. The company operates in two segments, Medical and Industrial. The Medical segment primarily focuses on physiological measurement, such as FFR and dPR in the coronary artery stenosis market; and supplies a range of miniature optical sensors to measure pressure and temperature used in integrated applications in other medical devices, as well as licenses its optical sensor technology.
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- Here’s Why the CPI Report will Dictate the Market Bottom
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
Receive News & Ratings for Opsens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opsens and related companies with MarketBeat.com's FREE daily email newsletter.